Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03029234

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma Clinical Trial

Official title:
An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03029234
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 3
Start date March 31, 2017
Completion date June 4, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06050512 - Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00932698 - Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma Phase 1
Terminated NCT03683277 - IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic Phase 2
Recruiting NCT04155749 - Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Phase 1
Recruiting NCT05530421 - Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03559764 - Study of BCMA CAR-T in Multiple Myeloma Early Phase 1
Completed NCT02144038 - Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Terminated NCT00664378 - Efficacy Study of CYT997 in Multiple Myeloma Phase 2
Terminated NCT03710915 - A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 1
Terminated NCT02223598 - A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Phase 1
Completed NCT03477643 - Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Recruiting NCT03661554 - BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma Early Phase 1